Brief: IRLAB Nominates New Candidate Drug, IRL757

IRLAB Therapeutics AB

21/03/2022 07:03

March 21 (Reuters) - IRLAB Therapeutics AB  IRLABa.ST :
    * IRLAB NOMINATES NEW CANDIDATE DRUG, IRL757, TO TREAT
APATHY IN
NEUROLOGICAL DISORDERS
    * IRL757 WILL BE DEVELOPED FOR TREATMENT OF APATHY IN PEOPLE
WITH
NEUROLOGICAL CONDITIONS
    * PHASE I CLINICAL STUDIES ARE PLANNED TO BEGIN EARLY Q3,
2023

Source text for Eikon:  ID:nMFN75H4jF 
Further company coverage:  IRLABa.ST 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))